



(12) Translation of
European patent specification

(11) NO/EP 2875011 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 221/22 (2006.01)
A61K 31/19 (2006.01)
A61K 31/5386 (2006.01)
C07C 53/18 (2006.01)
C07C 53/40 (2006.01)
C07D 451/12 (2006.01)
C07D 453/02 (2006.01)
C07D 471/04 (2006.01)
C07D 471/08 (2006.01)
C07D 498/08 (2006.01)
C07D 519/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.06.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.01.10
(86)	European Application Nr.	13742355.4
(86)	European Filing Date	2013.07.16
(87)	The European Application's Publication Date	2015.05.27
(30)	Priority	2012.07.17, US, 201261672709 P 2012.10.01, US, 201261708521 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Designated Extension States: Proprietor	BA ME Takeda Pharmaceutical Company Limited, 1-1, Doshomachi-4-chome, Chuo-ku, Osaka-shi,, Osaka 541-0045, JP-Japan
(72)	Inventor	HITCHCOCK, Stephen, 10410 Science Center Drive, San Diego, California 92121, US-USA MONENSCHIN, Holger, 10410 Science Center Drive, San Diego, California 92121, US-USA REICHARD, Holly, 10410 Science Center Drive, San Diego, California 92121, US-USA SUN, Huikai, 10410 Science Center Drive, San Diego, California 92121, US-USA KIKUCHI, Shota, 10410 Science Center Drive, San Diego, California 92121, US-USA MACKLIN, Todd, 10410 Science Center Drive, San Diego, California 92121, US-USA HOPKINS, Maria, 10410 Science Center Drive, San Diego, California 92121, US-USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	5-HT₃ RECEPTOR ANTAGONISTS
(56)	References Cited:	EP-A1- 0 469 449, EP-A1- 0 708 105, EP-A2- 0 200 444, WO-A2-2009/108551, US-A1- 2005 234 095, WO-A1-2009/023623

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelsen 1-(1-metyl-1*H*-pyrazol-4-yl)-N-((1*R*,5*S*,7*S*)-9-metyl-3-oksa-9-azabisyklo[3.3.1]-nonan-7-yl)-1*H*-indol-3-karboksamid, eller et farmasøytisk akseptabelt salt derav.
2. Farmasøytisk sammensetning, omfattende en forbindelse ifølge krav 1 og et farmasøytisk akseptabelt hjelpestoff.
3. Forbindelse ifølge krav 1, for bruk som et medikament.